GLP1RYour two copies: rs10305420C/rs10305420C
CCTypical response
The receptor that semaglutide and other GLP-1 drugs act on.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Weight managementExample report
Semaglutide
Ozempic, Wegovy
Use as directed
Your genes point to a typical response to this drug, with average weight loss and side effects.
The genes behind this label
The guidelines read one gene for semaglutide. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
GLP1RTypical response
Gene2Rx research summary
Evidence: moderateSee the drug page (Gene2Rx research summaries, opens in a new tab)
- In plain words
- Your genes point to a typical response to this drug, with average weight loss and side effects.
- What it means
- The Pro7/Pro7 form of the GLP1R signal peptide (rs10305420 C/C). The Leu7 (T) allele is the less common one in every ancestry group studied. Expected weight-loss efficacy and typical nausea/vomiting risk.
- What the research suggests
- Standard dosing and titration are expected to produce an average response.
About semaglutide
Semaglutide copies GLP-1, a gut hormone released after eating, and acts on the GLP-1 receptor in the pancreas, the gut and the brain.
- Used for
- Blood sugar control in type 2 diabetes; long-term weight reduction in obesity, or overweight with a weight-related condition; lowering the risk of heart attack and stroke in some people; Ozempic also for kidney disease with type 2 diabetes, and Wegovy injection for a form of fatty liver disease (MASH)
Others in weight management
Compare all 3 weight managementDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.